JPMorgan assumed coverage of InnovAge with an Underweight rating and $5 price target. The firm views current outpatient environment to be most favorable for companies with lower reimbursement exposure to federal funding. The analyst believes InnovAge is facing challenges balancing growth while navigating the regulatory backdrop.
